Search Results - "upadacitinib"
-
1
Are the goals of therapy achievable in patients with rheumatoid arthritis receiving upadacitinib in real clinical practice?
Published 2022-07-01Subjects: “…upadacitinib…”The aim of the study was to evaluate the effectiveness of UPA in RA patients in real clinical practice after 3 and 6 months of therapy.Material and methods. The study included 63 RA patients with high activity of the disease. Activity was assessed according to the DAS28 (ESR), DAS28 (CR P), SDAI, CD...
Get full text
Article -
2
The progress of rheumatology in the 21st century potential uses of upadacitinib in rheumatoid arthritis and other inflammatory rheumatic diseases
Published 2020-11-01Subjects: Get full textThe explanation of the mechanisms underlying the pathogenesis of rheumatoid arthritis (RA), along with the development of a wide range of biologics (bDMARDs), is among the major achievements of medicine in the 21st century. A new direction in the pharmacotherapy of inflammatory rheumatic diseases is...
Article -
3
Experience of using the drug upadacitinib in a child with severe atopic dermatitis
Published 2025-06-01Subjects: Get full textIntroduction. Atopic dermatitis (AtD) is a genetically determined chronic dermatosis with heterogeneous manifestations that can significantly affect the quality of life of patients. The disease has a complex pathogenesis, which significantly complicates its treatment. The JAK-STAT signaling pathway...
Article -
4
The first experience of using upadacitinib in the treatment of rheumatoid arthritis in real clinical practice (results of the multicenter project “RACURS”)
Published 2021-10-01Subjects: Get full textUpadacitinib (UPA), a JAK inhibitor, is a new therapeutic option that allows patients with insufficient response to therapy with basic anti-inflammatory drugs (DMARDs) or genetically engineered biological drugs (GEBDs) to achieve the goals of therapy for rheumatoid arthritis (RA). Despite the availa...
Article -
5
JAK Inhibitor and Crohn’s Disease
Published 2025-05-01Subjects: Get full textCrohn’s disease is a chronic inflammatory granulomatous disease of the gastrointestinal tract. The global incidence and prevalence of Crohn’s disease have significantly increased, largely due to genetic susceptibility, environmental changes, and advancements in diagnostic technology. In recent years...
Article -
6
Upadacitinib in daily practice for refractory atopic dermatitis in adolescents: a case series of the BioDay registry
Published 2025-12-01Subjects: Get full textPurpose Upadacitinib is approved for treating moderate-to-severe atopic dermatitis (AD) aged ≥12 years. We evaluated upadacitinib’s effectiveness and safety in AD adolescents in daily practice.Materials and methods Fifteen adolescent AD patients from the BioDay registry, treated with upadacitinib 15...
Article -
7
Successful Treatment of Upadacitinib in Prurigo Nodularis: A Case Report and Review of the Literature
Published 2025-05-01Subjects: Get full textBohui Li,1 Wo Yao,1 Ran Diao,1 Boyun Yang,1 Yongfang Wang,1 Ting Li,1 Liuya Ge,2 Huiying Wang1 1Department of Allergy and Clinical Immunology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, 310009, People’s Republic of China; 2Outpatient Care D...
Article -
8
Ultrasound Evaluation of Therapeutic Response to Tofacitinib and Upadacitinib in Patients with Rheumatoid Arthritis—Real-Life Clinical Data
Published 2025-05-01Subjects: Get full text<b>Background</b>: In recent years, musculoskeletal ultrasonography (MSUS) has established itself as a reliable method for evaluating disease activity in combination with clinical examination and laboratory tests. <b>Objectives</b>: In this pilot study, we aimed to evaluate t...
Article -
9
-
10
The use of selective Janus kinase inhibitor upadacitinib in a patient with psoriatic arthritis (clinical observation)
Published 2025-04-01Subjects: Get full textWe describe a patient with psoriatic arthritis (PSA) and palmoplantar psoriasis, resistant to standard therapy, who observed a significant decrease in disease activity on the background of upadacitinib at a dose of 15 mg/day. Remission was achieved by the 3rd month of treatment. No adverse phenomena...
Article -
11
Efficacy and Safety of Upadacitinib and Vedolizumab Combination for Refractory Orofacial Granulomatosis Associated with Panenteric Crohn’s Disease: A Case Report
Published 2025-03-01Subjects: Get full text<b>Background and Clinical Significance</b>: Orofacial granulomatosis is a rare but often disabling condition potentially associated with inflammatory bowel disease (IBD). Pathogenesis is not well understood, and no disease-specific approved treatment exists to date. <b>Case Presen...
Article -
12
Modern Strategies in the Pharmacotherapy of Inflammatory Bowel Diseases – A Literature Review
Published 2025-07-01Subjects: Get full textIntroduction and Aim: Inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis, are chronic, immune-mediated disorders of the gastrointestinal tract. Conventional therapies, such as corticosteroids, immunosuppressants, and biologics, do not consistently induce long-term r...
Article -
13
Efficacy and safety of upadacitinib for patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis
Published 2025-07-01Subjects: Get full textObjectiveThere is a growing array of options for the treatment of immune-mediated inflammatory diseases (IMIDs). To explore upadacitinib’s efficacy and safety in autoimmune disease treatment, we conducted this study.MethodsPubmed, Web of Science and Embase were searched for randomized controlled tri...
Article -
14
Treatment with Upadacitinib in Difficult-to-Treat (D2T) Psoriatic Arthritis (PsA): A National Multicenter Study of the First 134 Patients in Clinical Practice
Published 2025-05-01Subjects: Get full textUpadacitinib has demonstrated efficacy in psoriatic arthritis in clinical trials, but its real-world performance in difficult-to-treat PsA remains underexplored. This observational, multicenter, open-label study evaluated the efficacy and safety of upadacitinib in 134 patients with psoriatic arthrit...
Article -
15
Pathogenetic role of IL-4 and IL-13 in atopic dermatitis: The inhibitory pathways
Published 2025-03-01Subjects: Get full textThe review article is devoted to the two key Th2 cytokines, IL-4 and IL-13, which are directly involved in the immunopathogenesis of atopic dermatitis (AD). The identification of IL-4 and IL-13 in AD was first reported by Q. Hamid et al. in 1994. Since then, a number of studies have appeared confirm...
Article -
16
Janus kinase inhibitors in the treatment of psoriatic arthritis
Published 2022-02-01Subjects: Get full textThe article presents an analysis of literature data on the use of a new group of targeted synthetic disease-modifying antirheumatic drugs (DMARDs) Janus kinase (JAK) inhibitors – tofacitinib (TOFA) and upadacitinib (UPA) – in psoriatic arthritis (PsA). The results of randomized placebocontrolled cli...
Article -
17
Janus kinase inhibitors in immunoinflammatory diseases: 10 years of clinical practice in rheumatology
Published 2022-05-01Subjects: Get full textDespite great advances in the diagnosis and treatment of Immune-mediated inflammatory diseases (IMIDs), which have led to a significant improvement in the prognosis in many patients, the central medical problems of this pathology – restoring the quality of life and reducing mortality to the populati...
Article